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Background: Blocking the production of aldosterone represents an attractive therapeutic approach for reducing blood pressure (BP) and treating 
cardiovascular diseases. We evaluated the antihypertensive efficacy and safety of an aldosterone synthase inhibitor (ASI), LCI699, in patients with 
stage 1 and 2 hypertension as compared to placebo and the mineralocorticoid receptor antagonist eplerenone (EPL).
Methods: Following a 2 to 4-week washout/placebo run-in period, patients meeting the entry criteria (diastolic BP [DBP] ≥95 & <110 mmHg) 
were randomized (n=522) to 1 of 6 groups: LCI699 at 0.25 mg QD, 0.5 mg QD, 1.0 mg QD or 0.5 mg BID; EPL at 50 mg BID; or placebo (n=77-96 
per group) during an 8-week double-blind treatment period. Clinic and 24-hour ambulatory BPs were measured at baseline and Week 8. The primary 
objective of the study was to demonstrate superior reductions in DBP with LCI699 vs placebo.
Results: Baseline mean clinic and 24-hour BPs were 157.9/100.3 mmHg (systolic BP [SBP]/DBP) and 141.6/90.1 mmHg, respectively. Placebo-
subtracted changes from baseline to Week 8 in mean sitting SBP/DBP were: LCI699 0.25 QD (−7.1/−2.6 mmHg), LCI699 0.5 QD (−6.1/−2.1 
mmHg), LCI699 1.0 QD (−10.0/−4.5 mmHg), LCI699 0.5 BID (−7.1/−2.1 mmHg), EPL 50 BID (−11.1/−5.3 mmHg). All doses of LCI699 reduced 
SBP significantly more than placebo (p<0.01) and 1.0 mg QD LCI699 also produced a significantly greater reduction in DBP (p<0.01 vs placebo). 
The antihypertensive effect of LCI699 1.0 QD was not statistically different from EPL 50 BID. Data obtained with ambulatory BP monitoring were 
consistent with clinic BPs, with all doses of LCI699 lowering 24-hr mean SBP/DBP significantly greater than placebo (p<0.01) and achieving a 
placebo-subtracted reduction of 8.9/6.0 mmHg for LCI699 1.0 mg QD. The overall incidence of adverse events on LCI699 was low and similar to 
that of EPL and placebo. Transient hyperkalemia was observed in 3-5% of patients treated with EPL or any of the 3 highest doses of LCI699.
Conclusion: This study is the first clinical evaluation of an ASI for the treatment of essential hypertension. ASIs represent a potential novel 
approach to the management of high BP and other relevant cardiovascular diseases.
